News & Updates
Filter by Specialty:
Cefepime-taniborbactam trumps meropenem for complicated UTI
Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.
Cefepime-taniborbactam trumps meropenem for complicated UTI
26 Oct 2022
Baseline HRQOL predicts survival in after radical prostatectomy
Baseline health-related quality of life (HRQOL) among patients with localized high-risk prostate cancer prior to radical prostatectomy is an important and a strong predictor of survival, suggests a study.
Baseline HRQOL predicts survival in after radical prostatectomy
24 Oct 2022
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
24 Oct 2022
Thrice/week on par with twice/week ultrasound therapy for erectile dysfunction
Low-intensity pulsed ultrasound therapy three times per week has comparable therapeutic effects and safety as that of a twice-a-week session for mild-to-moderate erectile dysfunction (ED) in young and healthy men, reports a study.
Thrice/week on par with twice/week ultrasound therapy for erectile dysfunction
22 Oct 2022
Kidney transplant recipients see lower IgG production after COVID-19 jab
Vaccination against COVID-19 seems to be less effective among kidney transplant recipients, according to a recent study. Cessation or reduction of immunosuppressive treatments may help increase the production of immunoglobulin (Ig)G in these patients.
Kidney transplant recipients see lower IgG production after COVID-19 jab
14 Oct 2022
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.